247 related articles for article (PubMed ID: 23612012)
1. Targeting the BRAF V600E mutation in multiple myeloma.
Andrulis M; Lehners N; Capper D; Penzel R; Heining C; Huellein J; Zenz T; von Deimling A; Schirmacher P; Ho AD; Goldschmidt H; Neben K; Raab MS
Cancer Discov; 2013 Aug; 3(8):862-9. PubMed ID: 23612012
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
3. Targeting BRAF in multiple myeloma.
O'Donnell E; Raje NS
Cancer Discov; 2013 Aug; 3(8):840-2. PubMed ID: 23928771
[TBL] [Abstract][Full Text] [Related]
4. BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis.
Rustad EH; Dai HY; Hov H; Coward E; Beisvag V; Myklebost O; Hovig E; Nakken S; Vodák D; Meza-Zepeda LA; Sandvik AK; Wader KF; Misund K; Sundan A; Aarset H; Waage A
Blood Cancer J; 2015 Mar; 5(3):e299. PubMed ID: 25794135
[TBL] [Abstract][Full Text] [Related]
5. Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.
Raab MS; Lehners N; Xu J; Ho AD; Schirmacher P; Goldschmidt H; Andrulis M
Blood; 2016 Apr; 127(17):2155-7. PubMed ID: 26884375
[No Abstract] [Full Text] [Related]
6. Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.
Sharman JP; Chmielecki J; Morosini D; Palmer GA; Ross JS; Stephens PJ; Stafl J; Miller VA; Ali SM
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e161-3. PubMed ID: 24997557
[No Abstract] [Full Text] [Related]
7. SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma.
Moreaux J
EBioMedicine; 2015 Jan; 2(1):13-4. PubMed ID: 26137529
[No Abstract] [Full Text] [Related]
8. BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.
Bohn OL; Hsu K; Hyman DM; Pignataro DS; Giralt S; Teruya-Feldstein J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):e65-8. PubMed ID: 24445188
[No Abstract] [Full Text] [Related]
9. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Clinicopathologic Significance of BRAF V600E Mutation in Chinese Multiple Myeloma Patients.
Cheung CHY; Cheng CK; Lau KM; Ip RKL; Chan NCN; Tam THC; Wong RSM; Raghupathy R; Chan NPH; Ng MHL
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e315-e325. PubMed ID: 29807803
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib treatment of BRAF V600E-mutated malignant peripheral nerve sheath tumor.
Kaplan HG
J Natl Compr Canc Netw; 2013 Dec; 11(12):1466-70. PubMed ID: 24335681
[TBL] [Abstract][Full Text] [Related]
12. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
[TBL] [Abstract][Full Text] [Related]
13. CIC Mutation as a Molecular Mechanism of Acquired Resistance to Combined BRAF-MEK Inhibition in Extramedullary Multiple Myeloma with Central Nervous System Involvement.
Da Vià MC; Solimando AG; Garitano-Trojaola A; Barrio S; Munawar U; Strifler S; Haertle L; Rhodes N; Teufel E; Vogt C; Lapa C; Beilhack A; Rasche L; Einsele H; Kortüm KM
Oncologist; 2020 Feb; 25(2):112-118. PubMed ID: 32043788
[TBL] [Abstract][Full Text] [Related]
14. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
[No Abstract] [Full Text] [Related]
15. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
16. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.
Follows GA; Sims H; Bloxham DM; Zenz T; Hopper MA; Liu H; Bench A; Wright P; Van't Veer MB; Scott MA
Br J Haematol; 2013 Apr; 161(1):150-3. PubMed ID: 23278307
[No Abstract] [Full Text] [Related]
17. Successful Treatment of Metastatic Upper Tract Urothelial Carcinoma With Vemurafenib: Case Report.
Ji G; Qian Y
Clin Genitourin Cancer; 2017 Aug; 15(4):e719-e721. PubMed ID: 28024948
[No Abstract] [Full Text] [Related]
18. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
19. Major response to vemurafenib in patient with severe cutaneous Langerhans cell histiocytosis harboring BRAF V600E mutation.
Charles J; Beani JC; Fiandrino G; Busser B
J Am Acad Dermatol; 2014 Sep; 71(3):e97-9. PubMed ID: 25128147
[No Abstract] [Full Text] [Related]
20.
Boyle EM; Ashby C; Tytarenko RG; Deshpande S; Wang H; Wang Y; Rosenthal A; Sawyer J; Tian E; Flynt E; Hoering A; Johnson SK; Rutherford MW; Wardell CP; Bauer MA; Dumontet C; Facon T; Thanendrarajan S; Schinke CD; Zangari M; van Rhee F; Barlogie B; Cairns D; Jackson G; Thakurta A; Davies FE; Morgan GJ; Walker BA
Clin Cancer Res; 2020 May; 26(10):2422-2432. PubMed ID: 31988198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
